Epoetin alfa biosimilar - LG Chem

Drug Profile

Epoetin alfa biosimilar - LG Chem

Alternative Names: EPO; Espogen

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LG Life Sciences
  • Developer CHA University; Chong Kun Dang; LG Chem; LG Life Sciences; Ministry of Health & Welfare, Korea
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Cell stimulants; Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia
  • Phase II Cerebral palsy

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Cerebral-palsy(Combination therapy, In children, In infants) in South Korea
  • 24 Jun 2017 LG Life Sciences and Chong Kun Dang Pharmaceutical completes a clinical trial in Cerebral palsy (In infants, In children, Combination therapy) in South Korea (unspecified route) (NCT01991145)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top